Form 4: SpringWorks Therapeutics Director Daniel Lynch Sells Shares Under 10b5-1 Trading Plan

Director Daniel Lynch sold shares of SpringWorks Therapeutics (SWTX) common stock on February 10, 2025, under a pre-arranged trading plan.

Summary

• Daniel Lynch, a director at SpringWorks Therapeutics, sold shares of the company's common stock on February 10, 2025.
• The sales were executed under a pre-arranged trading plan (Rule 10b5-1) adopted on May 3, 2024.
• A total of 174,990 shares were sold in multiple transactions at varying weighted average prices.
• The sales occurred in three tranches: 69,766 shares at $53.2287, 39,634 shares at $54.8783, and 65,600 shares at $55.5145.
• Following these transactions, Mr. Lynch directly owns 130,944 shares of SpringWorks Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports the sale of shares by a director under a pre-existing trading plan. There's no inherent positive or negative implication.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the size of Mr. Lynch's overall holdings and the typical trading patterns of insiders at comparable biotech companies.
• However, the use of a 10b5-1 trading plan is a standard practice among corporate insiders to avoid accusations of illegal insider trading.
• Comparing the volume of shares sold to the average daily trading volume of SWTX stock could provide context on the potential market impact of these sales.

Stakeholder Impact

• The sale of shares by a director could potentially create short-term selling pressure on the stock.
• However, the existence of a 10b5-1 trading plan mitigates concerns that the sales are based on negative inside information.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Daniel Lynch, Form 4, share sale, Rule 10b5-1, director, insider trading